Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonia Vallet

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
Breast Cancer Research : BCR|February 28, 2016
Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implicationsMuhammad Hasan Bashari, Fengjuan Fan, Sonia Vallet, et al.
Bone|January 22, 2013
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myelomaSamantha Pozzi, Mariateresa Fulciniti, Hua Yan, et al.
Cancer Research|June 11, 2009
Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myelomaJing Zhang, Martin Sattler, Giovanni Tonon, et al.
Molecular Oncology|September 11, 2025
PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolismInge Oudaert, Lauren van den Broecke, Osman Aksoy, et al.
Blood|May 7, 2009
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myelomaMariateresa Fulciniti, Pierfrancesco Tassone, Teru Hideshima, et al.
British Journal of Haematology|September 1, 2007
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cellsTeru Hideshima, Laurence Catley, Noopur Raje, et al.
Molecular Cancer Therapeutics|April 8, 2010
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myelomaDiana Cirstea, Teru Hideshima, Scott Rodig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical propertiesSamantha Pozzi, Sonia Vallet, Siddhartha Mukherjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2011
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomideLoredana Santo, Teru Hideshima, Diana Cirstea, et al.
Blood|February 28, 2004
Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disordersMarco Ladetto, Mara Compagno, Irene Ricca, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
Breast Cancer Research : BCR|February 28, 2016
Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implicationsMuhammad Hasan Bashari, Fengjuan Fan, Sonia Vallet, et al.
Bone|January 22, 2013
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myelomaSamantha Pozzi, Mariateresa Fulciniti, Hua Yan, et al.
Cancer Research|June 11, 2009
Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myelomaJing Zhang, Martin Sattler, Giovanni Tonon, et al.
Molecular Oncology|September 11, 2025
PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolismInge Oudaert, Lauren van den Broecke, Osman Aksoy, et al.
Blood|May 7, 2009
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myelomaMariateresa Fulciniti, Pierfrancesco Tassone, Teru Hideshima, et al.
British Journal of Haematology|September 1, 2007
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cellsTeru Hideshima, Laurence Catley, Noopur Raje, et al.
Molecular Cancer Therapeutics|April 8, 2010
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myelomaDiana Cirstea, Teru Hideshima, Scott Rodig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical propertiesSamantha Pozzi, Sonia Vallet, Siddhartha Mukherjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2011
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomideLoredana Santo, Teru Hideshima, Diana Cirstea, et al.
Blood|February 28, 2004
Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disordersMarco Ladetto, Mara Compagno, Irene Ricca, et al.
Pageof 8